LC and LC–MS Study of the Bioavailability and Metabolites of TM208 after Oral and Intravenous Administration to Rat

Jiao Wang,Yan Song,Jianmei Zhang,Xiaona Li,Xiaomei Ling,Runtao Li,Jingrong Cui

DOI: https://doi.org/10.1365/s10337-010-1697-4

2010-01-01

Chromatographia

Abstract:4-Methylpiperazine-1-carbodithioic acid 3-cyano-3,3-diphenylpropyl ester hydrochloride (TM208) is a new compound expected to become a new drug because of excellent in vivo and in vitro anticancer activity and low toxicity. A new, specific and sensitive LC method was set up for detecting the bioavailability of TM208 after oral administration. Samples were extracted with ethyl acetate after oral and intravenous administration. The retention times of TM208 and plunarizine (I.S.) were 5.5 and 9.9 min, respectively. The linear range was 0.125–50 μg mL−1. The accuracy (error, %) for three concentrations was 2.7–16.6%. Intra-day precision (as RSD) was 1.6–6.9% and inter-day precision was 7.6–11.5%. Extraction recovery of TM208 was 84.15–89.51% and that of the I.S. was 83.3%. Results from stability testing indicated that samples should be analyzed within 24 h or frozen immediately for later analysis. The bioavailable fraction (F) calculated by use of a non-compartment model was 63.3%. Pharmacokinetic data for TM208 were: mean residence time 24.3 and 5.1 h, V d 186.2 and 35.5 L kg−1, and Cl 6.9 and 4.2 L h−1 kg−1 after oral and intravenous administration, respectively. LC–MS comparison of the metabolites after the two methods of administration showed the kind and content of metabolites of TM208 in rat urine after intravenous administration were more than after oral administration. The experimental results show that the low anticancer activity of TM208 after intravenous administration is related to rapid elimination of the drug, and that the kind and content of metabolites do not affect the bioactivity of TM208.